Middleton & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Middleton & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-1,852	Closed	-$208K	–	159
2014 Q3	$208K	Buy	+1,852	New	+$176K	0.05%	155

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Middleton & Co's VRTX Position: Q4 2014 in Review

Middleton & Co sold out of Vertex Pharmaceuticals (VRTX) in Q4 2014, closing a stake of 1,852 shares — an estimated $208K sold.

Middleton & Co first reported a position in VRTX in Q3 2014 and held it in 1 quarter. The position peaked at $208K in Q3 2014. 475 funds tracked by Wall St. Rank hold VRTX as of Q4 2014.

Middleton & Co reported no remaining Vertex Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Middleton & Co sold 1,852 Vertex Pharmaceuticals shares in Q4 2014, an estimated $208K.
Middleton & Co first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 1 quarter.
Middleton & Co's Vertex Pharmaceuticals position peaked at $208K in Q3 2014.
475 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2014.

Based on Middleton & Co's 13F filing for Q4 2014, filed 23 Jan 2015.